Adhesion G protein-coupled receptors (aGPCRs) constitute a structurally and functionally distinct group within the superfamily of GPCRs. In 2015, the International Union of Pharmacology invited the Adhesion GPCR Consortium to publish a comprehensive review about aGPCRs and establish a unified nomenclature. Since then, substantial progress has been made in delineating the biological roles, molecular architecture, biochemical properties, expression profiles, ligand repertoire, and activation and signaling strategies of aGPCRs. Commensurate with these advances, their relevance to human pathophysiology has become increasingly apparent. In a coordinated effort, the Adhesion GPCR Consortium has reviewed recent progress in this field and provides a comprehensive assessment of the current understanding of aGPCR biology, including a focus on human and mammalian aGPCRs, their evolutionary origins, methodological approaches, and model systems for their investigation, as well as emerging approaches for their therapeutic targeting. SIGNIFICANCE STATEMENT: Adhesion G protein-coupled receptors are versatile cell-surface proteins that integrate structural, biochemical, and physiological functions, with major roles in health and disease. This review summarizes current knowledge of their molecular features, functions in diverse model systems, and emerging opportunities for therapeutic targeting, providing a comprehensive resource that connects basic biology with translational applications across multiple scientific disciplines.
Cancer progression relies on cellular transition states accompanied by changes in the functionality of adhesion molecules. The gene for adhesion G protein-coupled receptor latrophilin-3 (aGPCR Lphn3 or ADGRL3) is targeted by tumor-specific somatic mutations predominantly affecting the conserved GAIN domain where most aGPCRs are cleaved. However, it is unclear how these GAIN domain-altering mutations impact Lphn3 function. Here, we studied Lphn3 cancer-related mutations as a proxy for revealing unknown GAIN domain functions. We found that while intra-GAIN cleavage efficiency was unaltered, most mutations produced a ligand-specific impairment of Lphn3 intercellular adhesion profile paralleled by an increase in cell-matrix actin-dependent contact structures for cells expressing the select S810L mutation. Aberrant remodeling of the intermediate filament vimentin, which was found to coincide with Lphn3-induced modification of nuclear morphology, had less impact on the nuclei of S810L expressing cells. Notoriously, receptor signaling through G13 protein was deficient for all variants bearing non-homologous amino acid substitutions, including the S810L variant. Analysis of cell migration paradigms revealed a non-cell-autonomous impairment in collective cell migration indistinctly of Lphn3 or its cancer-related variants expression, while cell-autonomous motility was potentiated in the presence of Lphn3, but this effect was abolished in S810L GAIN mutant-expressing cells. These data identify the GAIN domain as an important regulator of Lphn3-dependent cell motility, thus furthering our understanding of cellular and molecular events linking Lphn3 genetic somatic mutations to cancer-relevant pathogenesis mechanisms.
Receptor activity–modifying protein 3 (RAMP3) heterodimerizes with the G protein–coupled receptor (GPCR) calcitonin receptor-like receptor (CLR) to form the receptor for the prolymphangiogenic peptide adrenomedullin (AM). RAMP3 allosterically regulates CLR to coordinate signaling, internalization, and endosomal recycling after stimulation with AM. Here, we used proximity proteomics to identify components of the RAMP3 interactome that regulated CLR and characterized how the interactome changed in response to AM. We identified unconventional myosin VI (MYO6), an actin-based molecular motor, as a proximal RAMP3-CLR interactor. In primary human lymphatic endothelial cells, the knockdown of MYO6 inhibited the AM-stimulated activation of the G protein Gα s and the kinases ERK and AKT but enhanced cAMP accumulation, thus increasing the activity of the kinase PKA and the transcription factor CREB. Furthermore, MYO6 inhibition blocked AM-dependent RAMP3-CLR internalization and trafficking to Rab5-positive endosomes, suggesting that signaling endosomes in primary lymphatic endothelial cells inhibit cAMP generation. Last, knockdown of MYO6 affected AM-mediated adherens junction remodeling and migration. Thus, identifying components of the RAMP3-CLR interactome has revealed a spatiotemporal regulator of AM signaling in lymphatic endothelial cells.